A few months ago I showed you a method, backed by science and driven by numbers, not hype, of making money in biotech.

The sector is notoriously hit-or-miss, but this strategy heavily tilts the odds in your favor.

Two distinct lists emerge from this method. One has stocks that Verdad and Associates, the firm that came up with this method, is actually buying.

These are the highest-conviction signals in the framework. When a biotech-specialist firm with a documented track record is actively adding to a position and someone inside the company is buying shares on the open market simultaneously, that is a meaningful convergence of informed opinion.

The second list casts the net somewhat wider. These are companies held by multiple biotech-specialist funds with strong historical track records in the space, where recent insider buying or institutional add-on activity has occurred in at least one qualified holder.

None of this is a recommendation to buy any specific stock, of course. Both lists are offered as a starting point for your own research, sized appropriately as the speculative allocation it is.

Today, we’re adding six new stocks to that first list. You can always see full watchlist right here.

logo

This is the part that matters.

No publisher. No overhead. Four strategies built to beat the market.

Get Full Access

Already a subscriber? Sign in

Premium members get:

  • Small-Cap Momentum Portfolio — beats the market 16 of the last 20 years
  • Equity REITs Portfolio — beat the S&P 500 by 10%+ annually since 1972
  • Small-Cap Deep Value Portfolio — Walter Schloss used this method to compound at 20% annually for 47 years
  • Alternative Fixed Income Portfolio — 10%+ yields, low drama
  • Weekly macro video — credit spreads, NFCI, and hard data. No noise, no politics.
  • Quarterly biotech watchlist — smart money tracking, insider buying, a decade of backtested data. A hitlist, not a portfolio.

Reply

Avatar

or to participate

More From Tim Melvin’s Flagship Report

View more
caret-right